Evidence map›Paper›PMID 32469633›Full record

ArticleVector borne and zoonotic diseases (Larchmont, N.Y.)2020

What We Need to Consider During and After the SARS-CoV-2 Pandemic.

Willy A Valdivia-Granda, Jürgen A Richt

Abstract read
In one paragraph

Article in Vector borne and zoonotic diseases (Larchmont, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Willy A Valdivia-GrandaOrion Integrated Biosciences, Inc., Manhattan, Kansas, USA.
Jürgen A RichtCenter of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Kansas State University, Manhattan, Kansas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even though extreme containment and mitigation strategies were implemented by numerous governments around the world to slow down the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the number of critically ill patients and fatalities keeps rising. This crisis has highlighted the socioeconomic disparities of health care systems within and among countries. As new CoVID policies and responses are implemented to lessen the impact of the virus, it is imperative (1) to consider additional mitigation strategies critical for the development of effective countermeasures, (2) to promote long-term policies and strict regulations of the trade of wildlife and live animal markets, and (3) to advocate for necessary funding and investments in global health, specifically for the prevention of and response to natural and manmade pandemics. This document considers some of these challenges.

Indexed as

BetacoronavirusGlobal HealthAnimalsBiological EvolutionCommunicable Disease ControlCoronavirus InfectionsCOVID-19COVID-19 VaccinesEpidemiological MonitoringGenome, ViralHost SpecificityHumansPandemicsPneumonia, ViralSARS-CoV-2Viral VaccinesCOVID-19 VaccinesViral VaccinesbiodefenseCoVID-19pandemicSARS-CoV-2

Identifiers

PMID32469633
PMCPMC7336884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.